Novo Nordisk AS (MEX:NVO) Marketable Securities : MXN7,745 Mil (As of Mar. 2025)

View and export this data going back to 2014. Start your Free Trial

What is Novo Nordisk AS Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Novo Nordisk AS's Marketable Securities for the quarter that ended in Mar. 2025 was MXN7,745 Mil.

Novo Nordisk AS's annual Marketable Securities increased from Dec. 2022 (MXN30,317 Mil) to Dec. 2023 (MXN39,334 Mil) but then declined from Dec. 2023 (MXN39,334 Mil) to Dec. 2024 (MXN31,195 Mil).

Novo Nordisk AS Marketable Securities Historical Data

The historical data trend for Novo Nordisk AS's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk AS Marketable Securities Chart

Novo Nordisk AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Marketable Securities

Get a 7-Day Free Trial

21,087.56

30,317.36

39,333.72

31,195.26

Novo Nordisk AS Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Marketable Securities	Get a 7-Day Free Trial															7,207.24	25,980.96	52,356.03	31,195.26	7,745.25

Novo Nordisk AS Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Novo Nordisk AS (MEX:NVO) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Novo Nordisk AS Marketable Securities Related Terms

Thank you for viewing the detailed overview of Novo Nordisk AS's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (MEX:NVO) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

NONOF:USA NVO:USA NOVOB:Mexico 0TDD:UK NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NVON:Canada N1VO34:Brazil NOV:Bulgaria NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, 2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.